Home » Stocks » KRYS

Krystal Biotech, Inc. (KRYS)

Stock Price: $53.65 USD 0.01 (0.02%)
Updated December 3, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.06B
Revenue (ttm) n/a
Net Income (ttm) -27.14M
Shares Out 19.68M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $53.65
Previous Close $53.64
Change ($) 0.01
Change (%) 0.02%
Day's Open 53.61
Day's Range 52.46 - 54.76
Day's Volume 59,588
52-Week Range 35.02 - 65.64

More Stats

Market Cap 1.06B
Enterprise Value 774.05M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 19.68M
Float n/a
EPS (basic) -1.48
EPS (diluted) -1.49
FCF / Share -1.78
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.43M
Short Ratio 9.80
Short % of Float n/a
Beta 1.20
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.19
Revenue n/a
Operating Income -28.73M
Net Income -27.14M
Free Cash Flow -35.02M
Net Cash 283.27M
Net Cash / Share 14.37
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -6.83%
ROE -10.66%
ROIC -115.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (10)

Buy 9
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$81.67*
(52.23% upside)
Low
54.0
Current: $53.65
High
115.0
Target: 81.67
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue----
Operating Income-22.08-11.92-4.77-1.14
Net Income-19.09-10.89-7.92-1.15
Shares Outstanding15.9011.205.360.88
Earnings Per Share-1.20-0.97-1.48-1.31
Operating Cash Flow-18.71-9.45-3.89-1.31
Capital Expenditures-6.40-2.23-0.21-0.02
Free Cash Flow-25.11-11.68-4.10-1.33
Cash & Equivalents19411249.591.92
Total Debt3.26--1.84
Net Cash / Debt19011249.590.08
Assets20911650.112.18
Liabilities6.112.890.641.89
Book Value20311349.470.29
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Krystal Biotech, Inc.
Country United States
Employees 51

Stock Information

Ticker Symbol KRYS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: KRYS
IPO Date September 20, 2017

Description

Krystal Biotech, a gene therapy company, develops and commercializes medicines for patients suffering from skin diseases in the United States. The company's lead product candidate is beremagene geperpavec (B-VEC), which has completed Phase I/II clinical study to treat dystrophic epidermolysis bullosa. It is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in preclinical stage for treating aesthetic skin conditions; KB104 that is in preclinical stage for the treatment of Netherton Syndrome; and KB5xx for treating chronic skin diseases, which is in discovery stage. The company was formerly known as Krystal Biotech, LLC and changed its name to Krystal Biotech, Inc. in March 2017. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.